Stay updated on Moderna Press Releases
Sign up to get notified when there's something new on the Moderna Press Releases page.
Latest updates to the Moderna Press Releases page
- Check4 days agoChange DetectedThe page has updated key financial figures and important legal news regarding Moderna, including a decrease in stock price and a confirmation of patent validity against Pfizer/BioNTech.SummaryDifference100%
- Check12 days agoChange DetectedThe page has updated key information regarding Moderna's COVID-19 vaccine, including a new price of $29.56 and the European Commission's approval for the updated vaccine targeting the SARS-CoV-2 variant LP.8.1, while previous pricing and several earlier announcements have been removed.SummaryDifference98%
- Check19 days agoChange DetectedThe pricing has increased from $32.20 to $34.01, and stock availability has risen from 6.01M to 6.61M.SummaryDifference3%
- Check26 days agoChange DetectedModerna has received U.S. FDA approval for its RSV vaccine, mRESVIA, for adults aged 18-59 at increased risk for RSV disease, while the previous approval for its COVID-19 vaccine, Spikevax, in children has been removed from the page.SummaryDifference82%
- Check33 days agoChange DetectedThe page now displays 26 news items from the year 2025, including the significant addition of Moderna receiving full U.S. FDA approval for its COVID-19 vaccine for children at increased risk.SummaryDifference7%
- Check40 days agoChange DetectedThe page now displays 25 news items from the year 2025, including a significant announcement from Moderna regarding positive Phase 3 results for a seasonal influenza vaccine.SummaryDifference4%
Stay in the know with updates to Moderna Press Releases
Enter your email address, and we'll notify you when there's something new on the Moderna Press Releases page.